ReviewIntegrated pharmacy research & practice2018
Management of gastroesophageal reflux disease in adults: a pharmacist's perspective.
Review in Integrated pharmacy research & practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care.Pharmacy (Basel, Switzerland) · 2025Review
- Article
- The Saudi Gastroenterology Association consensus on the clinical care pathway for the diagnosis and treatment of GERD.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Article
- Assessment and treatment of reflux-like symptoms in the community: a multidisciplinary perspective.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- Review
- Potential effects of carbon monoxide donor and its nanoparticles on experimentally induced gastric ulcer in rats.Inflammopharmacology · 2023Article
- Intrauterine exposure to omeprazole increases the risk of teeth morphological anomalies in the offspring of a murine model.Odontology · 2023Article
- Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.BMC gastroenterology · 2022Article
- Review of recent evidence on the management of heartburn in pregnant and breastfeeding women.BMC gastroenterology · 2022Review
- Survey-Based Analysis of Current Trends for Prescribing Gastrointestinal Protectants among Small-Animal General Practitioners in Portugal.Veterinary sciences · 2021Article
- A retrospective study on the evaluation of the symptoms, medications and improvement of the quality of life of patients undergoing robotic surgery for gastroesophageal reflux disease.Experimental and therapeutic medicine · 2021Article
- Different Effects of Aerobic Exercise and Diaphragmatic Breathing on Lower Esophageal Sphincter Pressure and Quality of Life in Patients with Reflux: A Comparative Study.Middle East journal of digestive diseases · 2021Article
- Barrett's Esophagus and Intestinal Metaplasia.Frontiers in oncology · 2021Review
- The Impact of Direct-to-Consumer Pharmaceutical Advertising on Public Knowledge of Gastroesophageal Reflux Disease: A Study on Over-the-Counter Proton Pump Inhibitors.Patient preference and adherence · 2020Article
- Effectiveness of a Patient-Centered Weight Management Model in a Community Pharmacy: An Interventional Study.Patient preference and adherence · 2020Article
- Personal, academic and stress correlates of gastroesophageal reflux disease among college students in southwestern Saudi Arabia: A cross-section study.Annals of medicine and surgery (2012) · 2019Article
- Alternative Treatments for Minor GI Ailments.Innovations in pharmacy · 2019Review
- Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is a common gastrointestinal diagnosis, a leading reason for endoscopy and cause of potentially serious complications, resulting in significant individual and system-wide health burden. Approximately one quarter of people living in western countries have experienced GERD, and the prevalence appears to be on the rise. Risk factors for GERD include hiatus hernia, obesity, high-fat diet, tobacco smoking, alcohol consumption, pregnancy, genetics, and some medications. The cardinal symptoms of GERD are troublesome heartburn and regurgitation. GERD is identified by taking a patient-centered history and if necessary can be classified by endoscopic investigation. The role of the pharmacist in the management of GERD is to confirm the diagnosis by history taking, confirm there are no alarming signs or symptoms that require referral to a doctor, and recommendation of short-term therapy to control symptoms. Effective pharmacological treatments for GERD include antacids, alginate, histamine H2 receptor antagonists, and proton pump inhibitors. This narrative review includes a comparison of the efficacy and safety of these treatments and pertinent information to help pharmacists advise patients with GERD on their appropriate use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.